U.S. markets closed

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.84-1.05 (-4.06%)
At close: 04:00PM EDT
25.50 +0.66 (+2.66%)
After hours: 06:55PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close25.89
Bid24.90 x 800
Ask25.50 x 800
Day's Range24.75 - 26.04
52 Week Range18.21 - 58.00
Avg. Volume1,645,340
Market Cap3.288B
Beta (5Y Monthly)-0.58
PE Ratio (TTM)2.76
EPS (TTM)8.99
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est52.71
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
31% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for VIR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vir Biotechnology, Inc.
    VIR: Lowering target price to $20.00VIR BIOTECHNOLOGY INC has an Investment Rating of SELL; a target price of $20.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program

    – Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – – Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June – SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an

  • Motley Fool

    Buy the Dip on These 3 Healthcare Stocks

    With the S&P 500 down over 23% year to date, investors looking for safety are eyeing the healthcare industry. Taylor Carmichael (Vir Biotechnology): Vir Bio is down about 45% in 2022, but it is one of my highest-confidence positions in healthcare right now. When the Food and Drug Administration gave Vir -- and its partner, GlaxoSmithKline -- an Emergency Use Authorization (EUA) for its COVID-19 treatment sotrovimab (trademark Xevudy), demand for the drug skyrocketed.

  • GlobeNewswire

    Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022

    SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accepted for one oral and two poster presentations at the International Liver Congress™ 2022 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place in London and online June 22-26. The oral presentation will highlight new dose and duration data from a Phase 2